Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Biophytis S.A.

Report full results of Parts 1 and 2 of the COVA Phase 2-3 trial

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
26 Feb 2021
Due
30 Jun 2021
Checked
26 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“results from the full study (Part 1 and Part 2) expected in Q2 2021, subject to any delays in patient recruitment or retention”

What we found

Evidence strength A What the grades mean

Filings dated 2021-07-01, after the Q2 2021 deadline, say the second interim analysis results are now expected in Q3 2021, with 176 of 310 required patients recruited.

  • A
    Biophytis S.A. 6-K filed 2021-07-01 Regulatory filing · published 1 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “Results of this second interim analysis (IA2) as regards to safety and efficacy are now expected in Q3 2021.” ✓ confirmed on the page
  • A
    Biophytis S.A. 6-K filed 2021-07-01 Regulatory filing · published 1 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “176 patients have been recruited in total over the 310 required for the release of the full results.” ✓ confirmed on the page
  • A
    Biophytis S.A. 6-K filed 2021-07-01 Regulatory filing · published 1 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “results of second interim analysis are expected in Q3 2021” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
Full results of COVA trial Parts 1 and 2
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
High
Conditional
Yes: subject to delays in patient recruitment or retention, supply chain, regulatory authorizations, and COVID-19-related delays
Depends on
Regulatory, Supplier

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Biophytis S.A.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C768946-024740 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.